Safety, effectiveness, and outcomes of concomitant use of highly active antiretroviral therapy with drugs for tuberculosis in resource-poor settings
- 1 March 2006
- journal article
- review article
- Published by Elsevier in The Lancet
- Vol. 367 (9514) , 944-945
- https://doi.org/10.1016/s0140-6736(06)68387-6
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Efavirenz levels and 24-week efficacy in HIV-infected patients with tuberculosis receiving highly active antiretroviral therapy and rifampicinAIDS, 2005
- Does immune reconstitution syndrome promote active tuberculosis in patients receiving highly active antiretroviral therapy?AIDS, 2005
- Risk Factors for Active Tuberculosis after Antiretroviral Treatment Initiation in AbidjanAmerican Journal of Respiratory and Critical Care Medicine, 2005
- Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretroviralsPublished by Elsevier ,2005
- Severe Hepatotoxicity Associated with Nevirapine Use in HIV‐Infected SubjectsThe Journal of Infectious Diseases, 2005
- Efficacy and safety of Efavirenz in HIV patients on Rifampin for tuberculosisThe Brazilian Journal of Infectious Diseases, 2004
- Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort studyThe Lancet, 2002
- Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapyAIDS, 2002